These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37208128)

  • 1. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
    Märkl F; Benmebarek MR; Keyl J; Cadilha BL; Geiger M; Karches C; Obeck H; Schwerdtfeger M; Michaelides S; Briukhovetska D; Stock S; Jobst J; Müller PJ; Majed L; Seifert M; Klüver AK; Lorenzini T; Grünmeier R; Thomas M; Gottschlich A; Klaus R; Marr C; von Bergwelt-Baildon M; Rothenfusser S; Levesque MP; Heppt MV; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
    Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
    Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
    Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
    J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
    Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL
    J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
    Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
    Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
    Kobold S; Steffen J; Chaloupka M; Grassmann S; Henkel J; Castoldi R; Zeng Y; Chmielewski M; Schmollinger JC; Schnurr M; Rothenfußer S; Schendel DJ; Abken H; Sustmann C; Niederfellner G; Klein C; Bourquin C; Endres S
    J Natl Cancer Inst; 2015 Jan; 107(1):364. PubMed ID: 25424197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
    Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 10. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures.
    Richards JO; Treisman J; Garlie N; Hanson JP; Oaks MK
    Cytometry A; 2012 May; 81(5):374-81. PubMed ID: 22467596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
    Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
    J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
    Thibault C; Nelson H; Chapoval AI
    Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
    Ruf P; Schäfer B; Eissler N; Mocikat R; Hess J; Plöscher M; Wosch S; Suckstorff I; Zehetmeier C; Lindhofer H
    J Transl Med; 2012 Nov; 10():219. PubMed ID: 23134699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
    Park JA; Cheung NV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice.
    Riedle S; Rösel M; Zöller M
    Int J Cancer; 1998 Mar; 75(6):908-18. PubMed ID: 9506537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.